Sub analysis of Japanese patients with hemophilia B in rIX-FP clinical trial

DOI Web Site Open Access

Bibliographic Information

Other Title
  • 血友病B に対する半減期延長型遺伝子組換え凝固第IX 因子アルブミン融合タンパク製剤（rIX-FP）の第III 相臨床試験における日本人患者サブ解析

Search this article

Description

<p>A recombinant coagulation factor IX albumin fusion protein (rIX-FP, CSL654) was developed with an improved PK profile to support a longer dosing interval for routine prophylaxis treatment. Japanese subjects have participated in a Study CSL654_3001, phase 3 open label, multinational, pivotal study of rIX-FP. Male hemophilia B patients with no inhibitor, 12–65 years of age, at least 150 exposure days with previous FIX products were eligible for enrollment. 10 of the 63 Study 3001 subjects were recruited in Japan. The mean t1/2 of rIX-FP in Japanese and all subjects were 95 h and 102 h respectively. The mean annualized spontaneous bleeding rate in Japanese and all subjects were 12.8 and 14.6 respectively for on-demand treatment, 1.8 and 0.6 respectively for weekly prophylaxis regimen, 0.4 and 1.1 respectively for every 2 weeks prophylaxis regimen. No patient developed an inhibitor and no safety concerns were identified in Study 3001. The results of Japanese subjects were consistent with those observed for the global population. rIX-FP is safe and effective for preventing bleeding episodes at weekly and every 2 weeks dosing regimens in Japanese patients with hemophilia B.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top